Ganapolsky climate chambers: Cortexin, Noopept and related comparators
Comparison in people · 2008
- What was studied
- 301 men aged 20–24 across the full program. Selected tables compare 17 Cortexin, 18 Noopept, 17 Cerebrolysin and nine placebo participants, with historical controls in cold.
- Main finding
- In cold, Cortexin participants averaged 210 W versus 162 W with placebo. In heat, Noopept averaged 188 W versus 152 W with placebo.
Cortexin · cold (n=17) · 155 → 210 W vs 159 → 162 W with placebo · Before chamber to during exposure; the 210 W mean is marked p<0.05 versus placebo and historical controls.
Related evidence maps: Military & occupational ↗
Reported findings and study design
In cold, Cortexin participants averaged 210 W versus 162 W with placebo. In heat, Noopept averaged 188 W versus 152 W with placebo.
Tabai climatic chamber: −10°C with 2.5 m/s airflow, +45°C at 80% humidity, or 3,000 m simulated altitude. The abstract specifies 40 minutes for cold and heat and 90 minutes at altitude within a longer chamber session.
Population or model 301 men aged 20–24 across the full program. Selected tables compare 17 Cortexin, 18 Noopept, 17 Cerebrolysin and nine placebo participants, with historical controls in cold.
Dose, route and schedule
Intranasal amounts in the author abstract: Cortexin 0.5 mg, Noopept 0.1 mg, Cerebrolysin 43 mg, Dilept 0.1 mg, Semax 0.2 mg and Deltaran 20 mg. Oral Vinpotropil contained piracetam 400 mg and vinpocetine 5 mg. Arms and testing series differ.
Protocol source ↗ · Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cortexin · cold (n=17) | 155 → 210 W vs 159 → 162 W with placebo | Before chamber to during exposure; the 210 W mean is marked p<0.05 versus placebo and historical controls. |
| Noopept · heat (n=18) | 182 → 188 W vs 164 → 152 W with placebo | Before chamber to during exposure; the 188 W mean is marked p<0.05 versus placebo. |
| Cortexin · simulated altitude | 170 → 170 W vs 162 → 154 W with placebo | |
| Cerebrolysin · heat (n=17) | 194 → 138 W vs 164 → 152 W with placebo | |
| Dilept · cold (n=16) | 182 W during exposure | The author reports 12% higher than the historical untreated control. |
| Semax · cold (n=17) | 195 → 161 W | Separate comparison. The in-chamber group mean was near control. |
| Deltaran · cold (n=18) | 196 → 217 W | Separate comparison. The author reports a significant increase from the pre-chamber measure. |
Selected in-chamber PWC₁₇₀ means (W)
| Group | Cold | Heat | Simulated altitude |
|---|---|---|---|
| Cortexin (n=17) | 210 | 155 | 170 |
| Noopept (n=18) | 189 | 188 | 197 |
| Cerebrolysin (n=17) | 157 | 138 | 152 |
| Placebo (n=9) | 162 | 152 | 154 |
PWC₁₇₀ is the cycling workload at 170 beats/min. These are descriptive group means.
The ledger uses the 301-person dissertation total once for these related reports.
Source for these results ↗ · Reviewed 2026-11-17
Study limitations and source details
Study limitations
- Pre-chamber values reflect the testing protocol and are not established drug-free baselines. Small groups and multiple outcomes limit interpretation.
- Related 2007 journal and conference reports share investigators, treatments and chamber conditions. Matching workload means indicate overlap.
Related publications may describe some of the same participants or experiments.
Source details
Original dissertation author abstract · Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending.
Author abstract transcription; methods and selected work-capacity tables. Full dissertation scan pending.
Reported methods, results and evidence limitations
Sources checked
Added to the library
Citation
V. P. Ganapolsky. Ganapolsky climate chambers: Cortexin, Noopept and related comparators Development and Study of New Meteoadaptogens, Kirov Military Medical Academy doctoral author abstract
Related compounds
Cortexin
A polypeptide extract of animal cerebral cortex. Its active material is a mixture of low-molecular-weight peptides studied in neurological rehabilitation, stroke and pediatric neurology.
Noopept
Omberacetam (GVS-111), a synthetic derivative of the Pro–Gly dipeptide. Its chemical name is N-phenylacetyl-L-prolylglycine ethyl ester. Studies examined cognition and the metabolite cycloprolylglycine.
Cerebrolysin
An injectable hydrolysate of porcine brain tissue containing small peptides and free amino acids. Clinical studies have examined recovery after stroke and cognition in Alzheimer’s disease.
Dilept
GZR-123, an experimental peptidomimetic designed from a fragment of neurotensin, a signaling peptide. Human studies included psychiatric dose-finding and a comparison with risperidone.
Semax
A synthetic heptapeptide, Met–Glu–His–Phe–Pro–Gly–Pro (MEHFPGP). It combines residues 4–7 of adrenocorticotropic hormone (ACTH) with Pro–Gly–Pro and has been studied in ischemic stroke.
DSIP
Delta sleep-inducing peptide (DSIP) is a nine-amino-acid peptide, Trp–Ala–Gly–Gly–Asp–Ala–Ser–Gly–Glu. Its name comes from early sleep experiments. Later studies examined sleep, pain and withdrawal.